Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE: Siplizumab in New Onset Type 1 Diabetes
NCT06025110Phase 2Terminated
- Sponsor
- ITB-MED
- Start
- Jan 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of siplizumab in type 1 diabetes mellitus (T1D), sponsored by ITB-MED. Started Jan 2023; status: terminated.
02
Drugs
siplizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06025110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06025110.